Edited and Reviewed by: Francesco Onida, ASST Fatebenefratelli Sacco, Italy
*Correspondence: Hanna Brauner,
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
In the published article, there was an error in
Patient demographics and grouping variables, n=70.
| Characteristics | Value |
|---|---|
| Age, mean (SD), range, median (IQR), years | 63.0 (15.1), 27–90, 68 (23) |
| Gender, n (%) | |
| Females | 25 (36) |
| Males |
45 (64) |
| Mycosis fungoides | 55 (79) |
| Lymphomatoid papulosis | 10 (14) |
| Othera | 5 (7) |
| Disease durationb, mean (SD), median (range), years | 9.1 (11.6), 4.5 (0–52) |
| <2 years, n (%) | 20 (29) |
| ≥2 years, n (%) | 50 (71) |
| Current clinical stage for patients with MFc, n (%) | |
| IA | 36 (66) |
| IB | 15 (27) |
| IIA | 1 (2) |
| IIB | 2 (4) |
| IIIB | 1 (2) |
| mSWAT, mean (SD), median (range) | 12.8 (17.2), 4 (0–70) |
| Treatment, n (%) | |
| None +/- emollients | 19 (27) |
| Skin-directed therapy | 42 (60) |
| PUVA or UVB +/- topical steroids | 6 (14) |
| Topical steroids | 36 (86) |
| Systemic therapyd | 9 (13) |
| Education, n (%) | |
| Primary school or high school | 26 (37) |
| Higher education | 44 (63) |
aPrimary cutaneous anaplastic large cell lymphoma (n=2), Sézary syndrome (n=1), primary cutaneous peripheral T-cell lymphoma unspecified (n=2). bYears since diagnosis. cAccording to the tumor-node-metastasis-blood clinical stage classification. dSystemic therapies: acitretin n=3, alitretinoin n=2, prednisolone n=1, methotrexate n=2, alemtuzumab n=1.
IQR, interquartile range; MF, mycosis fungoides; mSWAT, modified severity-weighted assessment tool; PUVA, psoralen and ultraviolet A-type light; SD, standard deviation; UVB, ultraviolet B-type light.
“Disease durationb.”
In the published article, there was an error in
Overall informational needs and educational needs assessment tool domains among 70 patients with cutaneous T-cell lymphoma*.
| All |
Females |
Males |
p-value | Disease duration |
Disease |
p-value | Primary school or high school |
Higher education |
p-value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Overall informational needsa0–3 | 2.3 (0.83) |
2.6 (0.6) |
2.1 (0.9) |
|
2.1 (0.9) |
2.3 (0.8) |
0.316 | 2.0 (0.9) |
2.5 (0.7) |
|
| Domains | ||||||||||
| Disease process |
13.5 (4.4) |
15.0 (3.8) |
12.7 (4.5) |
|
14.6 (4.1) |
13.1 (4.5) |
0.099 | 12.9 (4.7) |
13.9 (4.2) |
0.481 |
| Treatmentsb
|
9.6 (3.1) |
10.6 (2.4) |
9.0 (3.3) |
|
10.7 (1.9) |
9.1 (3.4) |
0.117 | 9.7 (3.0) |
9.5 (3.2) |
0.948 |
| Feelings |
2.6 (2.2) |
3.1 (2.2) |
2.3 (2.2) |
0.150 | 2.9 (2.4) |
2.5 (2.2) |
0.511 | 3.3 (2.1) |
2.2 (2.2) |
|
| Self-management |
3.4 (2.0) |
3.9 (1.6) |
3.2 (2.1) |
0.178 | 3.8 (2.2) |
3.3 (1.9) |
0.232 | 3.8 (2.1) |
3.2 (1.8) |
0.100 |
| Support systems |
3.7 (2.2) |
4.3 (1.9) |
3.4 (2.4) |
|
4.7 (2.1) |
3.3 (2.2) |
|
4.3 (2.4) |
3.3 (2.1) |
0.085 |
| Total score** |
33.0 (11.1) |
36.8 (8.9) |
30.8 (11.7) |
|
37.6 (8.5) |
31.2 (11.6) |
0.051 | 34.7 (11.6) |
32.0 (10.8) |
0.303 |
*Cutaneous T-cell lymphomas include mycosis fungoides (n=55), lymphomatoid papulosis (n=10), primary cutaneous anaplastic large cell lymphoma (n=2), Sézary syndrome (n=1), and primary cutaneous peripheral T-cell lymphoma unspecified (n=2) aIn general, how much information do you want to receive about your lymphoma disease? (1 question bTreatments, missing n=1 (in 1/4 questions). **Including all domains, missing n=1. Presented as mean score (standard deviation) and mean percentage of maximum score. Statistically significant values are marked in bold.
Overall informational needs and educational needs assessment tool domains among 55 patients with mycosis fungoides.
| All** |
Females |
Males |
p-value | Disease duration |
Disease duration |
p-value | Primary school or high school |
Higher education |
p-value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Overall informational needsa
|
2.4 (0.76) | 2.9 (0.4) |
2.2 (0.8) |
|
2.2 (0.9) |
2.5 (0.7) |
0.315 | 2.1 (0.9) |
2.6 (0.6) |
|
| Domains | ||||||||||
| Disease process |
13.8 (4.5) |
15.7 (3.4) |
12.7 (4.7) |
|
15.1 (3.8) |
13.3 (4.6) |
0.105 | 13.1 (5.0) |
14.2 (4.2) |
0.508 |
| Treatments |
9.8 (3.2) |
11.0 (2.1) |
9.1 (3.5) |
|
10.9 (1.6) |
9.4 (3.5) |
0.208 | 9.6 (3.1) (80%) | 9.9 (3.3) |
0.507 |
| Feelings |
2.7 (2.3) |
3.2 (2.3) |
2.4 (2.2) |
0.239 | 3.3 (2.4) |
2.5 (2.2) |
0.261 | 3.4 (2.1) |
2.3 (2.3) |
0.092 |
| Self-management |
3.7 (1.9) |
4.2 (1.4) |
3.4 (2.1) |
0.232 | 4.6 (1.7) |
3.4 (1.9) |
|
4.2 (2.1) |
3.4 (1.8) |
0.127 |
| Support systems |
3.7 (2.3) |
4.4 (2.0) |
3.3 (2.4) |
0.054 | 5.1 (2.2) |
3.2 (2.2) |
|
4.5 (2.6) |
3.3 (2.1) |
0.080 |
| Total score* |
33.7 (11.6) |
38.5 (8.2) |
30.9 (12.4) |
|
39.0 (8.7) |
31.8 (11.9) |
0.052 | 34.7 (12.5) |
33.1 (11.1) |
0.557 |
aIn general, how much information do you want to receive about your lymphoma disease? (1 question). *Including all domains. Presented as mean score (standard deviation) and mean percentage of maximum score. Statistically significant values are marked in bold.
“Presented as mean score (standard deviation) and mean percentage of maximum score.”
A correction has been made to the
“The domain scores ranged from 0 to 18 and the total score from 0 to 51, with a higher score indicating a greater need for education.”
The corrected sentence appears below:
“The domain scores ranged from 0 to 18 (total score from 0 to 51). Each domain score was presented as a mean percentage of the maximum possible domain score.”
A correction has been made to the
“We found that 65% of the CTCL patients in the cohort, particularly females, expressed a need for education, especially regarding disease process and treatment.”
The corrected sentence appears below:
“CTCL patients in the cohort, particularly females, expressed a need for education, especially regarding disease process and treatment.”
A correction has been made to the Main text
“Therefore, to facilitate comparisons between domains, the total score was divided by the maximum possible score and presented as a mean percentage.”
The corrected sentence appears below:
“Therefore, to facilitate comparisons between domains, each domain score was presented as a mean percentage of the maximum possible domain score.”
A correction has been made to the Main text
“The questionnaire was adapted for the purpose of the present study and used several of the original questions (see Supplementary 1), translated from Swedish to English, with the original Swedish questionnaire attached).”
The corrected sentence appears below:
“The questionnaire was adapted for the purpose of the present study and used several of the original questions (see Supplementary 1), translated from Swedish to English, with the original Swedish questionnaire attached.”
A correction has been made to the Main text
This sentence previously stated:
“The answers did not differ significantly depending on disease duration (<2 years vs. = 2 years).”
The corrected sentence appears below:
“The answers did not differ significantly depending on disease duration (<2 years vs. ≥ 2 years).”
A correction has been made to the Main text,
“We found that 65% of the CTCL patients in the cohort, particularly females, expressed a need for education, especially regarding disease process and treatment.”
The corrected sentence appears below:
“CTCL patients in the cohort, particularly females, expressed a need for education, especially regarding disease process and treatment.”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.